Q2 2026 Alkermes Plc Earnings Call Transcript

Jul 28, 2026 / 12:00 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Alkermes PLC (ALKS) reported a 34% year-over-year increase in net sales from its proprietary product portfolio, reaching $411.7 million.
The company expanded access to its antipsychotic medicine, Livaldi, which is now covered for more than 80% of insured lives, potentially driving future prescription growth.
Alkermes PLC (ALKS) has a strong R&D pipeline with ongoing phase 3 programs for narcolepsy and phase 2 studies for idiopathic hypersomnia and ADHD.
The acquisition and integration of Avidel and the Loomisis brand have proceeded well, contributing positively to the company's financial results.
Alkermes PLC (ALKS) maintains a strong balance sheet with approximately $690 million in cash and total investments, providing flexibility for future investments.

Negative

The company faces uncertainty regarding the timing of generic market entry for Vivitrol, which could impact future sales.
Alkermes PLC (ALKS) reported a GAAP net income of only $0.5 million, indicating limited profitability despite strong sales growth.
R&D expenses increased significantly to $112.9 million, reflecting the costs associated with advancing the company's orexin portfolio.
The company anticipates expanded gross-to-net adjustments for Livaldi in the second half of the year, which could affect short-term financial performance.
There is potential competition from Takeda's upcoming launch of an orexin receptor agonist, which could impact Alkermes PLC (ALKS)'s market position in the sleep disorder segment.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ALKS.OQ - Alkermes Plc
Q2 2026 Alkermes Plc Earnings Call
Jul 28, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Yeah

Greetings.

Welcome to Alchemy's second quarter 2026 financial results conference call.

My name is Sherry, I will be your operator for today's call.

All participants will be placed on mute to prevent any background noise if you should require operator system from your telephide.

Please note this conference is being recorded, I will now turn the call over to Sandra Coombs, senior Vice President of Investor Relations and Corporate Affairs.

Sandy, you may now begin.

Good morning.

Welcome to the Alkermes PLC conference call to discuss our financial results and business update for the quarter ended June 30th, 2026.

With me today are Richard Pops, our CEO, Joshua

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.